Gene expression profiling of porokeratosis demonstrates similarities with psoriasis

Journal of Cutaneous Pathology

Volumn 31, Issue 10, 2004, Pages 657-664

  Hivnor, Chad ^a   Williams, Nathan ^a   Singh, Fiza ^a   VanVoorhees, Abby ^a   Dzubow, Leonard ^a   Baldwin, Donald ^a   Seykora, John ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM BINDING PROTEIN; PROTEIN S100A8; PROTEIN S100A9; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; DNA MICROARRAY; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICRODISSECTION; POROKERATOSIS; PSORIASIS;

GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINOCYTES; MIDDLE AGED; POROKERATOSIS; PSORIASIS; RNA, MESSENGER; UP-REGULATION;

EID: 7444259126     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0303-6987.2004.00247.x     Document Type: Article

References (46)

1. Freedberg IE, Wolff A, Austen K, Goldsmith L, Katz S, Fitzpatrick T. Dermatology in general medicine, 5th edn. New York: Mc Graw-Hill, 1999.
2. Lucker GP, Happle R, Steijlen PM. An unusual case of porokeratosis involving the natal cleft: porokeratosis ptychotropica? Br J Dermatol 1995; 132 (1): 150.
3. Stone N, Ratnavel R, Wilkinson JD. Bilateral perianal inflammatory verrucous porokeratosis (porokeratosis ptychotropica). Br J Dermatol 1999; 140 (3): 553.
4. Wallner J, Fitzpatrick J, Brice S. Verrucous porokeratosis of Mibelli on the buttock mimicking psoriasis. Cutis 2003; 72: 391.
5. Sasson M, Krain AD. Porokeratosis and cutaneous malignancy. A review. Dermatol Surg 1996; 22 (4): 339.
6. Shen CS, Tabata K, Matsuki M, Goto T, Yokochi T, Yamanishi K. Premature apoptosis of keratinocytes and the dysregulation of keratinization in porokeratosis. Br J Dermatol 2002; 147 (3): 498.
7. Otsuka F, Chi HI, Shima A, Ishibashi Y. Cytological demonstration of abnormal DNA ploidy in the epidermis of porokeratosis. Arch Dermatol Res 1988; 280 (1): 61.
8. Magee JW, McCalmont TH, LeBoit PE. Overexpression of p53 tumor suppressor protein in porokeratosis. Arch Dermatol 1994; 130 (2): 187 [comment].
9. Puig L, Alegre M, Costa I, Matias-Guiu X, de Moragas JM. Overexpression of p53 in disseminated superficial actinic porokeratosis with and without malignant degeneration. Arch Dermatol 1995; 131 (3): 353 [comment].
10. Nelson C, Cowper S, Morgan M. p53, mdm-2, and p21 waf-1 in the porokeratoses. Am J Dermatopathol 1999; 21 (5): 420.
11. Ninomiya Y, Urano Y, Yoshimoto K, et al. p53 gene mutation analysis in porokeratosis and porokeratosis-associated squamous cell carcinoma. J Dermatol Sci 1997; 14 (3): 173.
12. Ozkan S, Fetil E, Aydogan T, et al. Lack of TP53 mutations in a case of porokeratosis palmaris, plantaris et disseminata. Dermatology 2000; 201 (2): 158.
13. Gray MH, Smoller BS, McNutt NS. Carcinogenesis in porokeratosis. Evidence for a role relating to chronic growth activation of keratinocytes. Am J Dermatopathol 1991; 13 (5): 438 [comment].
14. Roop DR, Krieg TM, Mehrel T, Cheng CK, Yuspa SH. Transcriptional control of high molecular weight keratin gene expression in multistage mouse skin carcinogenesis. Cancer Res 1988; 48 (11): 3245.
15. Tyner AL, Fuchs E. Evidence for posttranscriptional regulation of the keratins expressed during hyperproliferation and malignant transformation in human epidermis. J Cell Biol 1986; 103 (5): 1945.
16. de Mare S, de Jong EG, van de Kerkhof PC. DNA content and Ks8 12 binding of the psoriatic lesion during treatment with the vitamin D3 analogue MC903 and betamethasone. Br J Dermatol 1990; 123 (3): 291.
17. Pei XF, Leigh IM, Watt FM. Changes in type I keratin expression associated with HPV16 transformation of human epidermal keratinocytes. Epithelial Cell Biol 1992; 1 (2): 84.
18. Holland DB, Wood EJ, Roberts SG, West MR, Cunliffe WJ. Epidermal keratin levels during oral 1-alpha-hydroxyvitamin D3 treatment for psoriasis. Skin Pharmacol 1989; 2 (2): 68.
19. Coven TR, Murphy FP, Gilleaudeau P, Cardinale I, Krueger JG. Trimethylpsoralen bath PUVA is a remittive treatment for psoriasis vulgaris. Evidence that epidermal immunocytes are direct therapeutic targets. Arch Dermatol 1998; 134 (10): 1263 [comment].
20. Lucke T, Choudhry R, Thom R, Selmer IS, Burden AD, Hodgins MB. Upregulation of connexin 26 is a feature of keratinocyte differentiation in hyperproliferative epidermis, vaginal epithelium, and buccal epithelium. J Invest Dermatol 1999; 112 (3): 354.
21. Labarthe MP, Bosco D, Saurat JH, Meda P, Salomon D. Upregulation of connexin 26 between keratinocytes of psoriatic lesions. J Invest Dermatol 1998; 111 (1): 72.
22. Rivas MV, Jarvis ED, Morisaki S, Carbonaro H, Gottlieb AB, Krueger JG. Identification of aberrantly regulated genes in diseased skin using the cDNA differential display technique. J Invest Dermatol 1997; 108 (2): 188.
23. Budunova IV, Carbajal S, Slaga TJ. The expression of gap junctional proteins during different stages of mouse skin carcinogenesis. Carcinogenesis 1995; 16 (11): 2717.
24. Takeda A, Higuchi D, Takahashi T, et al. Overexpression of serpin squamous cell carcinoma antigens in psoriatic skin. J Invest Dermatol 2002; 118 (1): 147.
25. Ruse M, Broome AM, Eckert RL. S100A7 (psoriasin) interacts with epidermal fatty acid binding protein and localizes in focal adhesion-like structures in cultured keratinocytes. J Invest Dermatol 2003; 121 (1): 132.
26. Broome AM, Ryan D, Eckert RL. S100 protein subcellular localization during epidermal differentiation and psoriasis. J Histochem Cytochem 2003; 51 (5): 675.
27. Semprini S, Capon F, Tacconelli A, et al. Evidence for differential S100 gene over-expression in psoriatic patients from genetically heterogeneous pedigrees. Hum Genet 2002; 111 (4): 310.
28. Hagens G, Roulin K, Hotz R, Saurat JH, Hellman U, Siegenthaler G. Probable interaction between S100A7 and E-FABP in the cytosol of human keratinocytes from psoriatic scales. Mol Cell Biochem 1999; 192 (1): 123.
29. Watson PH, Leygue ER, Murphy LC. Psoriasin (S100A7). Int J Biochem Cell Biol 1998; 30 (5): 567.
30. Alowami S, Qing G, Emberley E, Snell L, Watson PH. Psoriasin (S100A7) expression is altered during skin tumorigenesis. BMC Dermatol 2003; 3 (1): 1.
31. Lozinski AZ, Fisher BK, Walter JB, Fitzpatrick PJ. Metastatic squamous cell carcinoma in linear porokeratosis of Mibelli. J Am Acad Dermatol 1987; 16 (2 Pt 2): 448.
32. Machino H, Miki Y, Teramoto T, Shiraishi S, Sasaki MS. Cytogenetic studies in a patient with porokeratosis of Mibelli, multiple cancers and a forme fruste of Werner's syndrome. Br J Dermatol 1984; 111 (5): 579.
33. Brodkin RH, Rickert RR, Fuller FW, Saporito C. Malignant disseminated porokeratosis. Arch Dermatol 1987; 123 (11): 1521.
34. Abadir R, Zurowski S. Case report: squamous cell carcinoma of the skin in both palms, axillary node, donor skin graft site and both soles - associated hyperkeratosis and porokeratosis, Br J Radiol 1994; 67 (797): 507.
35. Sawai T, Hayakawa H, Danno K, Miyauchi H, Uehara M. Squamous cell carcinoma arising from giant porokeratosis: a case with extensive metastasis and hypercalcemia. J Am Acad Dermatol 1996; 34 (3): 507.
36. Anzai S, Takeo N, Yamaguchi T, et al. Squamous cell carcinoma in a renal transplant recipient with linear porokeratosis. J Dermatol 1999; 26 (4): 244.
37. Sasaki S, Urano Y, Nakagawa K, Nagae H, Nakanishi H, Arase S. Linear porokeratosis with multiple squamous cell carcinomas: study of p53 expression in porokeratosis and squamous cell carcinoma. Br J Dermatol 1996; 134 (6): 1151.
38. Urano Y, Sasaki S, Ninomiya Y, Oura H, Arase S. Immunohistochemical detection of p53 tumor suppressor protein in porokeratosis. J Dermatol 1996; 23 (5): 365.
39. Arranz-Salas I, Sanz-Trelles A, Bautista-Ojeda D. p53 alterations in porokeratosis. J Cutan Pathol 2003; 30: 455.
40. Otsuka F, Shima A, Ishibashi Y. Porokeratosis as a premalignant condition of the skin. Cytologic demonstration of abnormal DNA ploidy in cells of the epidermis. Cancer 1989; 63 (5): 891.
41. Knoell KA, Patterson JW, Wilson BB. Sudden onset of disseminated porokeratosis of Mibelli in a renal transplant patient. J Am Acad Dermatol 1999; 41 (5 Pt 2): 830 [comment].
42. Kanitakis J, Euvrard S, Faure M, Claudy A. Porokeratosis and immunosuppression. Eur J Dermatol 1998; 8 (7): 459.
43. Kanitakis J, Misery L, Nicolas JF, et al. Disseminated superficial porokeratosis in a patient with AIDS. Br J Dermatol 1994; 131 (2): 284.
44. Hacham-Zadeh S, Holubar K. Etretinate in the treatment of disseminated porokeratosis of Mibelli. Int J Dermatol 1985; 24 (4): 258.
45. Campbell JP, Voorhees JJ. Etretinate improves localized porokeratosis of Mibelli. Int J Dermatol 1985; 24 (4): 261.
46. Beer WE, Smith NP. Hyperkeratotic porokeratosis (Mibelli) with psoriasis - response to an aromatic retinoid. Clin Exp Dermatol 1984; 9 (5): 509.